02463nas a2200433   4500000000100000008004100001260001300042653002600055653002400081653001800105653002300123653001300146653002400159653001100183653001200194653002400206653002500230653002500255653002600280653002500306653003200331653001800363100001400381700001500395700001200410700001300422700001300435700001500448700001300463700001600476700001400492700001400506245019200520856004100712300001100753490000700764520124400771022001402015       1995                            d  c1995 Sep10aAntibodies, Bacterial10aAntigens, Bacterial10aB-Lymphocytes10aBacterial Proteins10aEthiopia10aHeat-Shock Proteins10aHumans10aleprosy10aLeprosy, Borderline10aLeprosy, lepromatous10aLeprosy, Tuberculoid10aLymphocyte Activation10aMycobacterium leprae10aRecombinant Fusion Proteins10aT-Lymphocytes1 aThole J E1 aJanson A A1 aKifle A1 aHowe R C1 aMcLean K1 aNurilygn A1 aFilley E1 aShannon E J1 aBulla G J1 aHermans J00aAnalysis of T-cell and B-cell responses to recombinant M. leprae antigens in leprosy patients and in healthy contacts: significant T-cell responses to antigens in M. leprae nonresponders.  uhttp://ila.ilsl.br/pdfs/v63n3a01.pdf  a369-800 v633 a<p>The recognition of a panel of recombinant Mycobacterium leprae antigens by T cells and B cells from 29 borderline tuberculoid/tuberculoid (BT/TT) and 18 lepromatous leprosy (LL) patients and from 21 healthy controls (HC) in leprosy-endemic regions of Ethiopia was examined. All 11 antigenic molecules tested (including M. leprae hsp 10, hsp18, hsp65 and several novel M. leprae antigens) were shown to be recognized by T cells, but clear quantitative differences existed between reactivities induced by individual antigens. Similar quantitative differences were observed when antibody responses to hsp10 and hsp65 antigens were determined. No associations were found between the antigen-specific responses and the subject status of either BT/TT and LL patients or HC. Fifteen percent of the patients who were nonresponsive to sonicates of M. leprae showed significant T-cell responses to one or more individual M. leprae antigens. This indicates that M. leprae constituents other than the proteins tested are responsible for the M. leprae-specific nonresponsiveness in these patients, which may be exploited for the design of vaccines or immunotherapeutic modalities aimed at inducing M. leprae-specific immunity in nonresponders.</p>
  a0148-916X